P
Peter S. Nelson
Researcher at Fred Hutchinson Cancer Research Center
Publications - 497
Citations - 57568
Peter S. Nelson is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 96, co-authored 425 publications receiving 47923 citations. Previous affiliations of Peter S. Nelson include University of Washington & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Pten Null Prostate Epithelium Promotes Localized Myeloid-Derived Suppressor Cell Expansion and Immune Suppression during Tumor Initiation and Progression
Alejandro J. Garcia,Marcus Ruscetti,Teresita L. Arenzana,Linh M. Tran,Daniella Bianci-Frias,Elysia Sybert,Saul J. Priceman,Lily Wu,Peter S. Nelson,Stephen T. Smale,Hong Wu +10 more
TL;DR: It is indicated that epithelium-associated tumor-initiating events trigger the secretion of inflammatory cytokines and promote localized MDSC expansion and immune suppression, thereby promoting tumor progression.
Journal ArticleDOI
Influence of Surgical Manipulation on Prostate Gene Expression: Implications for Molecular Correlates of Treatment Effects and Disease Prognosis
Daniel W. Lin,Ilsa Coleman,Sarah T. Hawley,Chung Y. Huang,Ruth Dumpit,David Gifford,Philip Kezele,Hau Hung,Beatrice S. Knudsen,Alan R. Kristal,Peter S. Nelson +10 more
TL;DR: Molecular analyses of surgical samples should recognize that transcript alterations occur rapidly, and these results are important when designing and analyzing molecular correlates of clinical studies.
Journal ArticleDOI
Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress
Michael D. Nyquist,Alexandra Corella,Ilsa Coleman,Navonil De Sarkar,Arja Kaipainen,Gavin Ha,Roman Gulati,Lisa S Ang,Payel Chatterjee,Jared M. Lucas,Colin C. Pritchard,Gail P. Risbridger,John T. Isaacs,Bruce Montgomery,Colm Morrissey,Eva Corey,Peter S. Nelson,Peter S. Nelson +17 more
TL;DR: While tumor cells lacking TP53/RB1 are highly resistant to all single-agent therapeutics tested, the combination of PARP and ATR inhibition is found to produce significant responses, reflecting a clinically exploitable vulnerability resulting from replication stress.
Journal ArticleDOI
Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort.
Jesse K. McKenney,Wei Wei,Sarah Hawley,Heidi Auman,Lisa F. Newcomb,Lisa F. Newcomb,Hilary Boyer,Ladan Fazli,Jeff Simko,Antonio Hurtado-Coll,Dean A. Troyer,Maria S. Tretiakova,Funda Vakar-Lopez,Peter R. Carroll,Matthew R. Cooperberg,Martin E. Gleave,Raymond S. Lance,Daniel W. Lin,Daniel W. Lin,Peter S. Nelson,Peter S. Nelson,Ian M. Thompson,Lawrence D. True,Ziding Feng,James D. Brooks +24 more
TL;DR: It is argued that Gleason score assignment by current consensus guidelines are not entirely optimized for clinical use, including active surveillance, and suggested that focal poorly formed gland and cribriform patterns should be in separate prognostic groups, as the latter is associated with worse outcome.
Journal ArticleDOI
PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer.
Ruoxiang Wang,Jianchun Xu,Outi R. Saramäki,Tapio Visakorpi,William M. Sutherland,Jianguang Zhou,Buer Sen,So Dug Lim,Nicola J. Mabjeesh,Mahul B. Amin,Jin-Tang Dong,John A. Petros,Peter S. Nelson,Fray F. Marshall,Haiyen E. Zhau,Leland W.K. Chung +15 more
TL;DR: As the only prostate-specific gene identified in the most frequently amplified genomic region in prostate cancer, PrLZ may be the link between chromosome 8q amplification and malignant transformation of the prostate epithelia.